Literature DB >> 25955112

Daily life consequences, cognitive impairment, and fatigue after transient ischemic attack.

E Kjörk1,2, C Blomstrand2, G Carlsson2, Å Lundgren-Nilsson2, C Gustafsson1.   

Abstract

OBJECTIVES: Studies suggest that fatigue and cognitive impairment may be present after transient ischemic attack (TIA), but little is known about consequences in daily life. The main aim was to longitudinally explore the presence of fatigue, cognitive impairment, and consequences in daily life including communication after clinically diagnosed TIA at 1 and 9 months after the event.
MATERIAL AND METHODS: A consecutive sample of 46 patients (23 women, 69 ± 12.3 years) was assessed at discharge from hospital and at 1 and 9 months after TIA regarding cognition, mental fatigue, tiredness, and activities of daily life. This served as basis for an interview concerning experienced changes related to the TIA.
RESULTS: Problems in daily life with probable association with the TIA were experienced by 37% (n = 45) of participants 9 months after the TIA event. Cognitive impairment was present in 40% (n = 44) after 1 month and 30% (n = 23) after 9 months. Mental fatigue was experienced by 26% (n = 42) after 1 month and 17% (n = 39) after 9 months. Communication problems were reported and increased from 7 to 14 participants between the two time points.
CONCLUSIONS: A third of the TIA patients experienced problems in performance of complex activities in daily life and often communication problems within the first 9 months. Cognitive impairment and mental fatigue could be factors influencing performance in daily life and at work, but this needs to be verified in a larger sample. The risk of activity limitations indicates need for multiprofessional support and systematic routines for TIA follow-up.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  activities of daily living; cognition; communication; long-term outcome; rehabilitation; stroke

Year:  2015        PMID: 25955112     DOI: 10.1111/ane.12435

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  Association of plasma trimethylamine-N-oxide levels with post-stroke cognitive impairment: a 1-year longitudinal study.

Authors:  Chen Zhu; Guangzong Li; Zhiyu Lv; Jing Li; Xiangming Wang; Jie Kang; Cheng Zhan
Journal:  Neurol Sci       Date:  2019-08-16       Impact factor: 3.307

Review 2.  Potential Therapeutics for Vascular Cognitive Impairment and Dementia.

Authors:  Miao-Kun Sun
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

3.  Experiences, needs, and preferences for follow-up after stroke perceived by people with stroke and healthcare professionals: A focus group study.

Authors:  Emma K Kjörk; Carlsson Gunnel; Åsa Lundgren-Nilsson; Katharina S Sunnerhagen
Journal:  PLoS One       Date:  2019-10-01       Impact factor: 3.240

4.  Identifying Sub-Acute Rehabilitation Needs Among Individuals After Transient Ischaemic Attack Using Rehab-Compass as a Simple Screening Tool in the Outpatient Clinic.

Authors:  Gustaf Magaard; Britt-Marie StÅLnacke; Ann SÖrlin; Fredrik Öhberg; Stina Berggren; Emma Grollmuss; Xiaolei Hu
Journal:  J Rehabil Med Clin Commun       Date:  2019-10-14

5.  Leukoaraiosis Mediates the Association of Total White Blood Cell Count With Post-Stroke Cognitive Impairment.

Authors:  Wanying Shan; Liang Xu; Yuan Xu; Zhuoyin Qiu; Jie Feng; Jie Zhao; Jingwen Wang
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

Review 6.  Pituitary dysfunction and association with fatigue in stroke and other acute brain injury.

Authors:  H A Booij; W D C Gaykema; K A J Kuijpers; M J M Pouwels; H M den Hertog
Journal:  Endocr Connect       Date:  2018-05-10       Impact factor: 3.335

7.  Long-term perceived disabilities up to 10 years after transient ischaemic attack.

Authors:  Jenni Andersson; Britt-Marie Stålnacke; Ann Sörlin; Gustaf Magaard; Xiaolei Hu
Journal:  J Rehabil Med       Date:  2021-03-22       Impact factor: 2.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.